Reviews medical records of sarcoma patients given immunotherapy
Looks at how well immunotherapy works for people with sarcoma.
Plain-language title generated from the registry record
Registry title: A Study Involving Collection of Samples and Data From Sarcoma Patients Receiving Immunotherapy
Key facts
- Where
- Basking Ridge, Commack, East White Plains, Middletown, Montvale, New York, and Uniondale, United StatesSee the 7 sites
Where in United States
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)Basking Ridge, United StatesNo longer taking part
- Memorial Sloan Kettering Cancer Center Suffolk - Commack (All Protocol Activities)Commack, United StatesNo longer taking part
- Memorial Sloan Kettering Westchester (All Protocol Activities)East White Plains, United StatesNo longer taking part
- Memorial Sloan Kettering Monmouth (All Protocol Activities)Middletown, United StatesNo longer taking part
- Memorial Sloan Kettering Bergen (All Protocol Activities)Montvale, United StatesNo longer taking part
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesNo longer taking part
- Memorial Sloan Kettering Nassau (All Protocol Activities)Uniondale, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Memorial Sloan Kettering Cancer Center
- Trial code
- NCT06113315
- Record updated
- 4 August 2026
- Original description
The researchers are doing this study to improve their knowledge about immunotherapy use and how effective it is as a treatment for people with sarcoma by collecting information from participants' medical records who have been treated with immune checkpoint blockade or T-cell receptor-based therapy.Read full original descriptionShow less
An Observational Study of Sarcoma Patients Treated With Immunotherapy at Memorial Sloan Kettering Cancer Center
The researchers are doing this study to improve their knowledge about immunotherapy use and how effective it is as a treatment for people with sarcoma by collecting information from participants' medical records who have been treated with immune checkpoint blockade or T-cell receptor-based therapy.
Inclusion: Participants must have a histologic diagnosis of sarcoma confirmed by an MSK pathologist; Any prospectively identified patient being treated or to be treated with an immune checkpoint inhibitor, such as anti-PD-1, anti-PD-L1, anti-CTLA-4, or anti-LAG3 inhibitor, either as monotherapy or in combination with additional systemic therapy OR any prospectively identified patient being treated or to be treated with ACT-based treatment including but not limited to lifileucil, Afamitresgene autoleucel, and letetresgene autoleuce o Novel immune checkpoints inhibitors that are developed after submission of this protocol will also be included) Please Note: there is no age requirement. Patients of all ages are eligible to enroll.
Exclusion: Patient unwilling to consent to collection of historical and longitudinal clinicopathologic data in the patient medical record from baseline (the period prior to ICB or ACT initiation), during, and after ICB or ACT treatment.